Direct perturbation of lens membrane structure may contribute to cataracts caused by U18666A, an oxidosqualene cyclase inhibitor
Open Access
- 1 July 2004
- journal article
- Published by Elsevier in Journal of Lipid Research
- Vol. 45 (7) , 1232-1241
- https://doi.org/10.1194/jlr.m300469-jlr200
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Discordant expression of the sterol pathway in lens underlies simvastatin-induced cataracts in ChbbJournal of Lipid Research, 2003
- Risk of Cataract in Patients Treated With StatinsArchives of internal medicine (1960), 2001
- Toxicologic Lesions Associated with Two Related Inhibitors of Oxidosqualene Cyclase in the Dog and MouseToxicologic Pathology, 2001
- Mutations in a Δ8-Δ7 sterol isomerase in the tattered mouse and X-linked dominant chondrodysplasia punctataNature Genetics, 1999
- Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations*Clinical Pharmacology & Therapeutics, 1998
- Clinical phenotype of desmosterolosisAmerican Journal of Medical Genetics, 1998
- Cholesterol and cataractsSurvey of Ophthalmology, 1996
- Defective Cholesterol Biosynthesis Associated with the Smith-Lemli-Opitz SyndromeNew England Journal of Medicine, 1994
- Mevalonic Aciduria — An Inborn Error of Cholesterol and Nonsterol Isoprene BiosynthesisNew England Journal of Medicine, 1986
- Mechanism of cataract production by 3-β(2-diethylaminoethoxy) androst-5-en-17-one hydrochloride, U18666A: An inhibitor of cholesterol biosynthesisExperimental Eye Research, 1979